TGTaylan Gurgenci

Taylan Gurgenci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Taylan Gurgenci has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Minimal clinically important differences and the illusion of precision

    by Taylan Gurgenci, Sharon Lee, Luc Farnan, Phillip Good

    Objective: Minimal clinically important differences (MCIDs) are used in palliative care trials to guide sample size calculations and to judge whether changes in patient-reported outcomes represent meaningful benefit. Several methods are used to estimate MCIDs. For the Total Symptom Distress Score (TSDS), two common approaches are the within-patient mean change and receiver-operating characteristic (ROC)-based method. MCIDs derived using these approaches often differ across otherwise similar studies. We examined whether this variability reflects limited sample size or whether commonly used ROC-based methods contribute to persistent instability. Methods: Data for 186 participants were drawn from two published randomised controlled trials. MCIDs were estimated using (1) the within-patient mean change (anchored to minimal improvement) and (2) ROC analysis to maximise Youden’s J. Stratified bootstrap resampling was performed at nominal sample sizes of 50, 100 and 150. Results: With increasing sample size, variability in ROC-derived MCIDs decreased only modestly and remained substantial even in large samples. Multiple thresholds showed near-equivalent discriminatory performance. At n=150, multiple near-optimal thresholds were observed in up to 85.4% of bootstrap samples. The differences in the threshold values were clinically relevant. In contrast, mean-change MCIDs converged towards more consistent values (approximately −6.5 TSDS points), with markedly lower clinically-relevant variability. Conclusion: When MCIDs are used as fixed thresholds for trial design or interpretation, mean-change approaches are more reproducible across plausible samples, whereas ROC-based MCIDs show greater variability that can meaningfully affect trial conclusions. Caution is therefore warranted when using single ROC-derived MCIDs in palliative care trials.

  • Validating the Minimal Clinically Important Difference for the Edmonton Symptom Assessment Scale (ESAS) Total Symptom Distress Score (TSDS)

    by Taylan Gurgenci, Seunghun Lee, Lachlan Webb, Anita Pelecanos, Dominic Eu, Claire Stokes, Phillip Good

  • Open Access

    Information environments, epistemic selves, and life’s end

    by Steve Matthews, Taylan Gurgenci

    This paper examines how information environments shape individuals in the construction of what we dub epistemic selfhood. Using euthanasia as an illustration, we argue that end-of-life decision-making potentially suffers from this process when epistemic selfhood is malformed leading to decisions that lack proper justification. Our argument draws on Ian Hacking’s constructivist account of selves via public conceptualizations of human kinds, and then moves to the case of euthanasia to show that normalization dynamics create the kind of person who is thereby hindered in the capacity to make rational end-of-life choices. This is brought into stark relief where legislative frameworks seek to expand the range of cases, e.g., in Canada, where eligibility criteria for mental illness alone is under consideration. Under these conditions vulnerable individuals, lacking epistemic security, may make poorly grounded, misguided, decisions. Thus, we should promote information environments that support prudent practical reasoning, including at life’s end.

  • Liver enzyme effects of medicinal cannabis in advanced cancer: a substudy of two randomised trials

    by Luke Scarborough, Janet Hardy, Taylan Gurgenci, Georgie Huggett, Anita Pelecanos, Lachlan Webb, Ristan Greer, Phillip Good

    Objectives: This substudy investigated whether medicinal cannabis causes an elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in patients with advanced malignancy and determined whether different cannabis formulations (cannabidiol (CBD) alone vs tetrahydrocannabinol (THC)/CBD combination) had differing effects on enzyme levels. Methods: This analysis used data from two multicentre, randomised, placebo-controlled trials of escalating doses of CBD (MedCan1) or THC/CBD (MedCan2), including 287 patients with advanced cancer. Participants received escalating doses of CBD, THC/CBD or placebo. ALT and AST levels were measured at baseline, day 14 and day 28. Results: Medicinal cannabis did not cause elevation of ALT or AST in patients with advanced malignancy at the doses studied (up to 600 mg CBD/day). No clinically meaningful differences in liver enzyme levels were observed between CBD-only and CBD/THC combination products. Furthermore, no patients in the cannabis groups exceeded the predefined thresholds of 3× upper limit of normal (ULN) (or 5× ULN in those with liver metastases) for ALT or AST. Conclusions: In patients with advanced malignancy enrolled in two clinical trials, medicinal cannabis products did not have a significant adverse impact on ALT or AST levels during the first 4 weeks of use at the doses studied.

  • Psychedelic drugs in palliative care: research agenda

    by Claire Stokes, Aaryan Khagram, Billie Metselaar, Taylan Gurgenci, Phillip Good

    Patients with life-limiting illnesses often experience profound emotional and spiritual challenges that conventional palliative care treatments may not fully alleviate. Psychedelics, with their potential to facilitate deep psychological insight, offer a promising approach to enhancing end-of-life care. Despite growing interest and emerging psychiatric applications, their use in palliative settings remains poorly understood, with existing studies limited by small sample sizes and low methodological quality. This article outlines a research agenda that prioritises adequately powered randomised controlled trials with patient-centred outcome measures, with an aim to inform policy and practice change.

  • Palliative management of breathlessness

    by Claire Stokes, Phillip Good, Jones Chen, Taylan Gurgenci

    The Australian Journal of General Practice (AJGP) aims to provide relevant, evidence-based, clearly articulated information to Australian general practitioners (GPs) to assist them in providing the highest quality patient care

  • Palliative management of depression in advanced cancer

    by Taylan Gurgenci, Jones Chen, Benjamin Jull, Claire Stokes, Robert Waugh, Phillip Good

    The Australian Journal of General Practice (AJGP) aims to provide relevant, evidence-based, clearly articulated information to Australian general practitioners (GPs) to assist them in providing the highest quality patient care

  • Management of constipation in people receiving palliative care

    by Jones Chen, Phillip Good, Claire Stokes, Taylan Gurgenci

    The Australian Journal of General Practice (AJGP) aims to provide relevant, evidence-based, clearly articulated information to Australian general practitioners (GPs) to assist them in providing the highest quality patient care


  • Pharmaceutical pitfalls in treating patients with advanced cancer

    by Taylan Gurgenci, Jones Chen, Benjamin Jull, Claire Stokes, Dominic Eu, Phillip Good

    The Australian Journal of General Practice (AJGP) aims to provide relevant, evidence-based, clearly articulated information to Australian general practitioners (GPs) to assist them in providing the highest quality patient care

  • Open Access

    Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol

    by Janet R. Hardy, Ristan M. Greer, Anita M. Pelecanos, Georgie E. Huggett, Alison M. Kearney, Taylan H. Gurgenci, Phillip D. Good

    Purpose: Patients with cancer commonly access cannabis hoping to relieve their symptoms. This study assessed whether a 1:1 10 mg/ml THC:CBD combination oil could improve total symptom burden in patients with advanced cancer over that provided by palliative care alone. Methods: Participants were randomised to medicinal cannabis (MC) or placebo oil; dose escalated over 14 days according to tolerance and efficacy and continued to day 28. Symptoms assessed using the Edmonton Symptom Assessment Scale (ESAS) were summated to give a total symptom distress score (TSDS). The primary outcome measure was the change from baseline in TSDS at day 14. Secondary outcomes included individual symptom scores, opioid use, participant-selected dose, QoL, psychological symptoms, global impression of change (GIC), and adverse effects. Results: The pre-planned sample size of 120 at day 14 was reached following the randomisation of 144 patients. Mean (SD) TSDS improved over time in both arms (− 6.30 (12.3) MC, − 6.98 (12.56) placebo, p = 0.76) to day 14 with no difference between arms. A statistically significant improvement in ESAS pain scores in the MC arm (mean (SD) − 1.42 (2.15) MC and − 0.46 (2.83) placebo, p = 0.04) was at the expense of greater psychomimetic toxicity. Improvement in general well-being was greater for the placebo. GIC and the pain component of QoL both favoured MC. Conclusions: Patients can be informed that a 1:1 THC:CBD combination cannabis oil was no better than palliative care alone in palliating symptoms in patients with advanced cancer. A small benefit in pain control was associated with greater toxicity. Trial registration: Australian New Zealand Clinical Trial Registry (ANZCTR): ACTRN12619000037101, 14/01/2019.